This is a working overview of GLP-1 receptor agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-14. Anything still debated is marked as such rather than presented as settled.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
| Property | Value | Notes |
|---|---|---|
| Molecular formula (free base) | C187H291N45O59 | Approximate; salt and hydrate forms differ |
| Molecular weight | ~4113.6 Da | Varies with counterion and hydration |
| Appearance | White to off-white powder | Lyophilized research material |
| Solubility class | Freely soluble in water | As formulated; native peptide less stable near neutral pH |
| Typical storage | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
https://www.calculator.net/half-life-calculator.html Comprehensive half-life calculator wiki: Decay Engine, Nucleonica.net (archived 2016) System Dynamics – Time Constants, Bucknell.edu Researchers Nikhef and UvA measure slowest radioactive decay ever: Xe-124 with 18 billion trillion years https://academo.org/demos/radioactive-decay-simulator/ Interactive radioactive decay simulator demonstrating how half-life is related to the rate of decay
Growth hormone-releasing peptide 6 (GHRP-6) (developmental code name SKF-110679), also known as growth hormone-releasing hexapeptide, is one of several synthetic met-enkephalin analogues that include unnatural D-amino acids, were developed for their growth hormone-releasing activity and are called growth hormone secretagogues. They lack opioid activity but are potent stimulators of growth hormone (GH) release. These secretagogues are distinct from growth hormone releasing hormone (GHRH) in that they share no sequence relation and derive their function through activation of a completely different receptor. This receptor was originally called the growth hormone secretagogue receptor (GHSR), but due to subsequent discoveries, the hormone ghrelin is now considered the receptor's natural endogenous ligand, and it has been renamed as the ghrelin receptor. Therefore, these GHSR agonists act as synthetic ghrelin mimetics. It has been discovered that when GHRP-6 and insulin are administered simultaneously, GH response to GHRP-6 is increased (1). However, the consumption of carbohydrates and/or dietary fats, around the administration window of GH secretagogues significantly blunts the GH release. A recent study in normal mice showed significant differences in body composition, muscle growth, glucose metabolism, memory and cardiac function in the mice being administered the GHRP-6 (2). There are still many questions regarding this fairly new compound.
the Standing Committee on Finance; the Election Committee; and the Committee of Privileges. The first session passed the Kuala Lumpur City Bill, the Transfer of Power Bill, and the Loan and Debt Bill.
=== Coolant additive === Graphene's high thermal conductivity suggests that it could be used as an additive in coolants. Preliminary research work showed that 5% graphene by volume can enhance the thermal conductivity of a base fluid by 86%. Another application due to graphene's enhanced thermal conductivity was found in PCR.
Sources: en.wikipedia.org
=== Birds === The skeletons of birds are adapted for flight. The bones in bird skeletons are hollow and lightweight to reduce the metabolic cost of flight. Several attributes of the shape and structure of the bones are optimized to endure the physical stress associated with flight, including a round and thin humeral shaft and the fusion of skeletal elements into single ossifications. Because of this, birds usually have a smaller number of bones than other terrestrial vertebrates. Birds also lack teeth or even a true jaw, instead having evolved a beak, which is far more lightweight. The beaks of many baby birds have a projection called an egg tooth, which facilitates their exit from the amniotic egg.
=== Proteins and nucleic acids === Daly developed methods for separating out the nuclei of tissues and measuring the base composition of purines and pyrimidines in desoxypentose nucleic acids. She concluded, among other things, that "no bases other than adenine, guanine, thymine, and cytosine were present in appreciable amounts." She investigated protein synthesis, including the role of cytoplasmic ribonucleoprotein in protein synthesis. Using radiolabeled amino acid glycine, she was able to measure how protein metabolism changed under feeding and fasting conditions in mice. This allowed her to monitor the activity of the cytoplasm as the radiolabeled glycine was taken up into the cell nucleus. In 1953, Watson and Crick described the structure of DNA. Accepting the Nobel Prize for this work in 1962, Watson cited one of Daly's papers on "The role of ribonucleoprotein in protein synthesis" as contributing to his work. After 1953, the cell nucleus research field was flooded with funding opportunities.
American Zionism was still in its infancy; in 1914 the Zionist Federation had a small budget of about $5,000 and only 12,000 members, despite an American Jewish population of three million but the Zionist organizations had recently succeeded, following a show of force within the American Jewish community, in arranging a Jewish congress to debate the Jewish problem as a whole. This impacted British and French government estimates of the balance of power within the American Jewish public. Avi Shlaim, emeritus Professor of International Relations in the University of Oxford, asserts that two main schools of thought have been developed on the question of the primary driving force behind the declaration, one presented in 1961 by Leonard Stein, a lawyer and former political secretary to the World Zionist Organization, and the other in 1970 by Mayir Vereté, then Professor of Israeli History at the Hebrew University of Jerusalem. Shlaim states that Stein does not reach any clear cut conclusions, but that implicit in his narrative is that the declaration resulted primarily from the activity and skill of the Zionists, whereas according to Vereté, it was the work of hard-headed pragmatists motivated by British imperial interests in the Middle East. Much of modern scholarship on the decision to issue the declaration focuses on the Zionist movement and rivalries within it, with a key debate being whether the role of Weizmann was decisive or whether the British were likely to have issued a similar declaration in any event.
Sources: en.wikipedia.org
It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.
Both deliver the same active peptide and act on the same receptor. The tablet includes an absorption enhancer because peptides are poorly taken up intact from the gut. Bioavailability of the oral route is substantially lower, so the two are not dose-equivalent.
No, it is entirely synthetic and does not occur in nature. Native GLP-1 is produced in the gut and pancreas, but the analog is manufactured by chemical synthesis or recombinant methods. Traces of the analog are not expected in people who never received it.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.